Taken together, the data presented here highlight a previously unexplored cellular pathway that might underlie the impairment of dopaminergic neurons in PD, further underscoring the potential of the GSK3β-SIRT2-α-synuclein signaling cascade as a viable target pathway for neuroprotective therapies. This evidence concerns the gene GSK3B and Parkinson disease.